Waldenstrom macroglobulinemia

Disease ID:1168
Name:Waldenstrom macroglobulinemia
Associated with:1 target
2 immuno-relevant ligands
Synonyms
lymphoplasmacytic lymphoma | Macroglobulinemia, Waldenstrom, somatic included | Macroglobulinemia, Waldenstrom, susceptibility to, 1 | WM
Description
A malignant B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and hypersecretion of monoclonal immunoglobulin M (IgM) protein
Database Links
Disease Ontology: DOID:0050747
OMIM: 153600
Orphanet: ORPHA33226

Targets

CXCR4
Comments:  Truncating mutations in the cytoplasmic tail domain of the CXCR4 gene are associated with Waldenstrom macroglobulinemia.
References:  1
Mutations:  CXCR4 is associated with 4 mutation. Click here for details

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
ibrutinib
Immuno Disease Comments: Approved drug for WM.
Clinical Use: Ibrutinib is approved to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of leukemia, especially patients with MCL who have received at least one prior therapy. In Feb 2014 ibrutinib was granted US FDA approval for treating chronic lymphocytic leukemia (CLL), as with MCL, this is only indicated for patients who have received at least one prior therapy. In February 2015, the US FDA expanded approval to include the treatment of Waldenström's macroglobulinemia (WM), which is a form of type of non-Hodgkin's lymphoma. Approval was granted based on the outcome of clinical trial NCT01614821 which indicated that the drug can offer a substantial improvement over contemporary therapies.
In August 2017, the FDA expanded approval to include treatment of chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy (e.g. first-line corticosteroid therapy). This approval followed results from clinical trial NCT02195869. The recommended dose of ibrutinib for cGVHD is 420 mg, orally once daily. | View clinical data
zanubrutinib
Immuno Disease Comments: Phase 3 clinical candidate for WM- NCT03332173 will evaluate clinical efficacy of single agent BGB-3111 in patients with relapsed/refractory WM.
Clinical Use: ClinicalTrials.gov list 14 registered BGB-3111 studies from Phase 1 to Phase 3. The Phase 3 trials are in patients with CLL or SLL (NCT03336333) and Waldenström's macroglobulinemia (NCT03053440). | View clinical data
Bioactivity Comments: In a cellular assay, zanubrutinib inhibits BTK with an IC50 of 20nM [2]. | View biological activity

References

Show »

1. Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P et al.. (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 123 (11): 1637-46. [PMID:24366360]

2. Wang Z, Guo Y. (2016) Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators. Patent number: US9447106B2. Assignee: Beigene Ltd.. Priority date: 25/04/2013. Publication date: 20/09/2016.